Skip to main content
. Author manuscript; available in PMC: 2013 Mar 1.
Published in final edited form as: Eur J Med Chem. 2012 Jan 12;49C:191–199. doi: 10.1016/j.ejmech.2012.01.010

Table 1.

Anti-HCV NS5B RdRp activity of STLC derivatives.

Compound % Inhibitiona IC50 (μM)b
STLC 12.6±2.3 n.d.
STDC 17.0±0.6 n.d.
NSC123139 23.1±1.6 n.d.
NSC136870 23.4±2.9 n.d.
NSC140909 30.9±3.7 n.d.
NSC123529 14.7±1.5 n.d.
NSC123138 28.3±5.9 n.d.
NSC126217 20.2±2.5 n.d.
1 22.4±5.4 n.d.
2 22.6±2.0 n.d.
3 36.8±2.4 n.d.
4 31.2±1.5 n.d.
5 20.5±1.1 n.d.
6 36.9±2.5 n.d.
7 43.5±0.8 n.d.
8 44.3±3.0 n.d.
9 60.0±3.4 39.7±0.9
10 17.2±2.9 n.d.
11 19.1±1.7 n.d.
12 22.5±2.2 n.d.
13 34.0±1.1 n.d.
14 33.1±0.7 n.d.
17a 31.7±1.8 n.d.
17b 28.7±2.1 n.d.
17c 27.4±4.2 n.d.
17d 24.0±4.5 n.d.
17e 36.7±2.1 n.d.
17f 36.0±1.0 n.d.
17g 33.3±2.3 n.d.
17h 28.3±5.9 n.d.
17i 16.1±3.0 n.d.
17j 14.0±3.3 n.d.
17k 22.0±1.4 n.d.
17l n.i. n.d.
F-3070 82.8±1.3 22.3±5.9
E-3205 40.2±0.7 n.d.
F-3065 76.7±2.4 24.6±6.0
a

Percent inhibition was determined at 100 μM concentration of the indicated compound and represents an average of at least two independent measurements in duplicate.

b

The IC50 values of the compounds were determined from dose-response curves employing 8–12 concentrations of each compound in duplicate in two independent experiments. Curves were fitted to data points using nonlinear regression analysis and IC50 values were interpolated from the resulting curves using GraphPad Prism 3.03 software.

n.d., not determined.

n.i., no inhibition.